FOLFIRINOX after first-line gemcitabine-based chemotherapy in advanced pancreatic cancer: a retrospective comparison with FOLFOX and FOLFIRI schedules:

Francesca Foschini,Fabiana Napolitano,Alberto Servetto,Roberta Marciano,Eleonora Mozzillo,Anna Chiara Carratu,Antonio Santaniello,Pietro De Placido,Priscilla Cascetta,Giovanni Butturini,Isabella Frigerio,Paolo Regi,Nicola Silvestris,Sabina Delcuratolo,Enrico Vasile,Caterina Vivaldi,Cataldo Bianco,Sabino De Placido,Luigi Formisano,Roberto Bianco

FOLFIRINOX after first-line gemcitabine-based chemotherapy in advanced pancreatic cancer: a retrospective comparison with FOLFOX and FOLFIRI schedules:

2020

Background:Pancreatic adenocarcinoma is the fourth leading cause of cancer-related death. In cases with metastasis, the combination of 5-fluorouracil, irinotecan, and oxaliplatin (FOLFIRINOX) or ge...

Keywords:

Internal medicine
Irinotecan
FOLFIRINOX
Oncology
Pancreatic cancer
Metastasis
Gemcitabine
FOLFIRI
Medicine
FOLFOX
Oxaliplatin

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations